Early value assessment consultation document for HTE10056 Digital therapy for chronic tic disorders and Tourette syndrome

Guidance development process

The medical technologies advisory committee has considered the evidence and the views of clinical and patient experts. EVA guidance recommendations are conditional while more evidence is generated to address uncertainty in their evidence base. NICE has included advice in this guidance on how to minimise any clinical or system risk of early access to treatment.

More evidence will be generated over the next 3 years to assess if the benefits of these technologies are realised in practice. NICE guidance will be reviewed to include this evidence and make a recommendation on the routine adoption of this technology across the NHS.

This document has been prepared for public consultation. It summarises the evidence and views that have been considered and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public. This document should be read along with the evidence (an EVA report).

The advisory committee is interested in receiving comments on the following:

Has all of the relevant evidence been taken into account?

Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

Are the recommendations sound, and a suitable basis for guidance to the NHS?

Equality issues

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the recommendations may need changing to meet these aims. In particular, please tell us if the recommendations:

could have a different effect on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology

could have any adverse effect on disabled people.

Please provide any relevant information or data you have about such effects and how they could be avoided or reduced.

Note that this document is not NICE's final guidance ondigital therapy for chronic tic disorders and Tourette syndrome. The recommendations in section 1 may change after consultation.

After consultation, NICE will consider the comments received. The final recommendations will be the basis for NICE's early value guidance.

Key dates:

Closing date for comments: 17 December 2024